# Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win

> **Open Intelligence Dossier** · First detected: 2026-10-19 22:40 UTC · Category: Business

## Executive Summary
Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug.

## Intelligence Brief
Current financial and pharmaceutical coverage centers on a major corporate acquisition involving Merck KGaA and Silence Therapeutics. According to reports from sources including Yahoo Finance, Merck Group, FirstWord Pharma, and Morningstar, Merck KGaA has agreed to purchase Silence Therapeutics in a transaction valued at $1.3 billion. This buyout follows a phase 2 win for an siRNA drug and builds directly upon a phase 3 win that occurred alongside a 130 percent takeover premium, which collectively energized rare blood-disease stocks on Monday. The reporting places heavy emphasis on the strategic pharmaceutical implications of the deal, specifically noting that the acquisition is designed to strengthen Merck Group&amp;#039;s rare disease pipeline.


FirstWord Pharma frames the transaction as a clear double-down by Merck KGaA on its rare disease buildout. Meanwhile, Morningstar broadens the financial lens by questioning whether various equities, including Silence Therapeutics and other related tickers, are obtaining fair deals for their respective shareholders during this wave of market activity. Context provided within the coverage highlights that the market environment is currently heavily influenced by significant valuation premiums and clinical trial milestones within the rare blood-disease sector. The combination of a phase 3 win, the notable 130 percent takeover premium, and the subsequent $1.3 billion acquisition announcement created a distinct focal point for investors tracking rare disease therapeutics and stock valuations at the start of the week.


Future developments will depend on how the transaction progresses toward completion and how shareholder value questions raised by market analysts are addressed. Coverage does not yet specify a finalized closing date for the acquisition, nor does it detail subsequent regulatory hurdles. Observers and shareholders will likely monitor upcoming financial filings and further commentary regarding the rare disease pipeline expansion by Merck Group.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Morningstar | Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxObTlhUC1HaWI0UVFxMUJDSHFNUFk1U01TTHpZV19ERjVGY2czRjQ5LXlSay0zMkF4TVlYaEI4bXpNcHFYSkdFdXl1b1BNSlEyeXo5VkRWNFZLUXFzd0Z1WENCNW9KdS1yUjZqTTdudzlmeVBwUHFhcVJQZUxEa0tHSVJYZUkzNzBFX2tsXzRQTHFfSVlxWXlxLWhfdFRTSWlQaEwxYnVsZ2w2SnBXNEhNM19RempRb2dWbThXTzZjRHQzQWN3?oc=5) |
| Yahoo Finance | A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxPUjNNUS0xZEJRUThXRjZaeFVLMVNpZFpJaXZwbWFVQkNsa2U0cG5mQjlUNV80UkZsb1VVc2VBYnAzU2ZaZkM4MHV5NVFiOU96djZDOTJoM0ZkOTJuZnpjcVdfWkQ0clNqeG1fV2lIRUhYN0kyMHNXQkRTMERIYTN3dndrSEpuc0NhTU9RcFhR?oc=5) |
| Merck Group | Acquisition of Silence Therapeutics to Strengthen Rare Disease Pipeline | [Source Link](https://news.google.com/rss/articles/CBMie0FVX3lxTE1hempRQkRPUHpFWWZiOUxhV3JldGlHQlpLRnlOc2pKXzJGT2xveWxnajkxMTN6LTNtWGVsa0lXbXhQY0x0aDkyaDQ4ZXJNSlFWZlBnbFU5eHBXVFVLeHc5Sk4wU3VVRUhsa0kzUXpVeFFOWDRVamlmaE4zNA?oc=5) |
| FirstWord Pharma | Merck KGaA doubles down on rare disease buildout with $1.3B Silence buy | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1RY1VhWTJrb2ZXTXdEbTFqZFp2eXNac1NKSVh6S0RoZmtMaWNGczZjczNLYlFDT2dFN0tvSG5FZF9ZeVZjMlZZTWFsTW5NX2ZDLWV3?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-19/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-win*
